Merck Sharp + Dohme Corp.

Ning Shao

Anandan Palani

Robert G Aslanian

Ashwin Umesh Rao

Xianhai Huang

Kevin D McCormick

Li Dong

Christopher W Boyce

Michael Berlin

Ying Huang

Younong Yu

Pauline C Ting

Rongze Kuang

Jianhua Chao

Manuel De Lera Ruiz

Junying Zheng

Walter Won

Salem Fevrier

Jie Wu

Hongjun Zhang

Phieng Siliphaivanh

Purakkattle J Biju

Wei Zhou

Rachel Nicola MacCoss

Brian Alexander McKittrick

Scott D Edmondson

Jason D Brubaker

Dong Xiao

Gerald Wayne Shipps, Jr

Joey Lee Methot

Joshua Close

Robert D Mazzola, Jr

Zhuyan Guo

Santhosh Francis Neelamkavil

Peter Orth

Joon Jung

Johannes H Voigt

Xiao Chen

John W Butcher

Eric Mertz

John P Caldwell

Robert Jason Herr

Qin Jiang

Haiqun Tang

Jun Qin

Elizabeth Helen Kelley

Xiaohua Huang

Yi Zang

Michelle Martinez

Scott Peterson

Jiafang He

Pawan Dhondi

Lana Michele Rossiter

Jolicia Polivina Gauuan

Andrew J Leyhane

Clifford Cheng

Xianfeng Sun

Qi Zeng

Youngong Yu

Purakkattle Johny Biju

Scott L Peterson

Joshua T Close

Pawan K Dhondi

Brian A Mckittrick

Kevin D Mccormick

Rachel N Maccoss

Robert D Mazzola

Joon O Jung

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Factor XIa inhibitors

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

[object Object]

The present invention relates to novel quinoxaline compounds of Formula I: as Fatty Acid Binding Protein ('FABP') inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Substituted quinoxalines as inhibitors of fatty acid binding protein

The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R, R, R, R, R, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction.

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators

Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. 

Bicyclic heterocyclic derivatives and methods of use thereof

Growing community of inventors

Watchung, NJ, United States of America

Ning Shao